"Prodrugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
| Descriptor ID |
D011355
|
| MeSH Number(s) |
D26.675
|
| Concept/Terms |
Prodrugs- Prodrugs
- Pro-Drugs
- Pro Drugs
- Drug Precursors
- Precursors, Drug
|
Below are MeSH descriptors whose meaning is more general than "Prodrugs".
Below are MeSH descriptors whose meaning is more specific than "Prodrugs".
This graph shows the total number of publications written about "Prodrugs" by people in this website by year, and whether "Prodrugs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 4 | 1 | 5 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 3 | 2 | 5 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prodrugs" by people in Profiles.
-
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer. Prostate. 2024 Mar; 84(4):349-357.
-
Design of carboxymethylcellulose-conjugated polymeric prodrug micelles for enhanced in vivo performance of docetaxel. Int J Biol Macromol. 2023 Dec 31; 253(Pt 8):127690.
-
d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res. 2023 Sep; 531:108861.
-
Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers. J Med Chem. 2022 10 27; 65(20):13813-13832.
-
Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates. Nat Microbiol. 2022 10; 7(10):1536-1546.
-
Inhibiting protein synthesis to treat malaria. Science. 2022 06 03; 376(6597):1049-1050.
-
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol. 2022 10; 82(4):365-373.
-
A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 07 01; 65:116761.
-
A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. Drug Deliv. 2021 Dec; 28(1):240-251.
-
Structure-guided microbial targeting of antistaphylococcal prodrugs. Elife. 2021 07 19; 10.